TP53 mutations diminish the efficacy of TKIs in patients with EGFR-mutant NSCLC and are associated with a poorer prognosis, particularly for those with non-disruptive, non-missense mutations, and mutations outside the DNA-binding domain (DBD), specifically in exons 6 and 7. The gene discussed is TP53; the disease is non-small cell lung carcinoma.